<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077285</url>
  </required_header>
  <id_info>
    <org_study_id>03-099</org_study_id>
    <secondary_id>MSKCC-03099</secondary_id>
    <nct_id>NCT00077285</nct_id>
  </id_info>
  <brief_title>Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma</brief_title>
  <official_title>A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk Rhabdomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan and carboplatin, work in different&#xD;
      ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving irinotecan together with carboplatin&#xD;
      as upfront window therapy (first-line therapy) works in treating patients with newly&#xD;
      diagnosed intermediate-risk or high-risk rhabdomyosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with newly diagnosed intermediate- or high-risk&#xD;
           rhabdomyosarcoma treated with upfront window therapy comprising irinotecan and&#xD;
           carboplatin.&#xD;
&#xD;
        -  Determine the acute toxic effects of this regimen combined with radiotherapy in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the safety and feasibility of this regimen in these patients.&#xD;
&#xD;
        -  Determine the rate of local control achieved in patients treated with this regimen in&#xD;
           combination with intensity-modulated radiotherapy.&#xD;
&#xD;
        -  Determine the safety and feasibility of administering maintenance therapy comprising&#xD;
           irinotecan to patients with high-risk rhabdomyosarcoma treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate, preliminarily, in vitro measurements of angiogenesis with clinical features&#xD;
           (extent of disease), response to therapy, and outcome in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of this regimen, in terms of improved outcomes,&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Courses 1 and 2: Patients receive carboplatin IV over 1 hour on day 1 and irinotecan IV&#xD;
           over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for a total of 2&#xD;
           courses.&#xD;
&#xD;
        -  Courses 3-5: Patients receive vincristine IV on days 1, 8, and 15; dexrazoxane IV over&#xD;
           15-30 minutes, doxorubicin IV over 15-30 minutes, and cyclophosphamide IV over 1 hour on&#xD;
           days 1 and 2; and filgrastim (G-CSF) subcutaneously (SC) once daily beginning on&#xD;
           approximately day 3 and continuing until blood counts recover. Treatment repeats every&#xD;
           21 days for a total of 3 courses.&#xD;
&#xD;
      Some patients may undergo surgical resection of the tumor after completion of course 5. After&#xD;
      course 5, patients undergo radiotherapy once daily, 5 days a week, for 4-5.5 weeks.&#xD;
&#xD;
        -  Courses 6 and 7*: Patients receive vincristine IV and carboplatin IV over 1 hour on day&#xD;
           1; irinotecan IV over 1 hour on days 1-5 and 8-12; and G-CSF SC once daily beginning on&#xD;
           approximately day 13 and continuing until blood counts recover. Treatment repeats every&#xD;
           21 days for a total of 2 courses.&#xD;
&#xD;
      NOTE: *Patients who develop disease progression during courses 1 or 2 do not receive further&#xD;
      irinotecan and carboplatin. Instead, patients receive ifosfamide and etoposide as in courses&#xD;
      8 and 9.&#xD;
&#xD;
        -  Courses 8 and 9: Patients receive vincristine IV on day 1; etoposide IV over 1 hour and&#xD;
           ifosfamide IV over 2 hours on days 1-5; and G-CSF SC once daily beginning on&#xD;
           approximately day 6 and continuing until blood counts recover. Treatment repeats every&#xD;
           21 days for a total of 2 courses.&#xD;
&#xD;
        -  Course 10: Patients receive vincristine IV on days 1, 8, 15, 22, 29, 36, and 43;&#xD;
           dexrazoxane IV over 15-30 minutes, doxorubicin IV over 15-30 minutes, and&#xD;
           cyclophosphamide IV over 1 hour on days 1 and 2; and filgrastim SC beginning on&#xD;
           approximately day 3 and continuing until blood counts recover (1 course).&#xD;
&#xD;
        -  Course 11 and 12: Patients receive etoposide IV over 1 hour and ifosfamide IV over 2&#xD;
           hours on days 1-5 and G-CSF SC once daily beginning on approximately day 6 and&#xD;
           continuing until blood counts recover. Treatment repeats every 21 days for a total of 2&#xD;
           courses.&#xD;
&#xD;
      Patients with high-risk disease proceed to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy*: Patients receive irinotecan IV over 1 hour on days 1-5 and 8-12.&#xD;
           Treatment repeats every 21 days for a total of 6 courses.&#xD;
&#xD;
      NOTE: *Patients who develop disease progression during courses 1 or 2 do not receive further&#xD;
      irinotecan.&#xD;
&#xD;
      In all courses, treatment continues in the absence of unacceptable toxicity or disease&#xD;
      progression or recurrence after initial response.&#xD;
&#xD;
      Patients are followed monthly for 1 year, every 3 months for 1 year, every 6 months for 1&#xD;
      year, and then annually thereafter.&#xD;
&#xD;
      *Starting with A(8), patients will undergo PET Scans instead of Bone Scans, at the discretion&#xD;
      of the PI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and feasibility</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of local control</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of in vitro measurements of angiogenesis with clinical features (extent of disease), response to therapy, and outcome</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms of improved outcomes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexrazoxane hydrochloride</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>pts with intermediate- and high-risk rhabdomyosarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Newly diagnosed, previously untreated histologically-proven rhabdomyosarcoma,&#xD;
             undifferentiated sarcoma, or ectomesenchymoma. Histology must be confirmed by a MSKCC&#xD;
             pathologist.&#xD;
&#xD;
        Intermediate- or high-risk features as defined below:&#xD;
&#xD;
          -  All patients with Stage 4 tumors (distant metastases).&#xD;
&#xD;
        Intermediate Risk:&#xD;
&#xD;
          -  All patients with non-metastatic undifferentiated sarcoma or alveolar RMS or&#xD;
             ectomesenchymoma with alveolar features (regardless of age, site, size, stage, or&#xD;
             degree of initial surgical resection);&#xD;
&#xD;
          -  All patients &lt; 1 year of age with non-metastatic embryonal RMS or ectomesenchymoma&#xD;
             with embryonal features (regardless of site, stage, or degree of initial surgical&#xD;
             resection).&#xD;
&#xD;
          -  Patients ≥ 1 year of age with Stage 2 or 3 (unfavorable site [see Appendix I] and&#xD;
             either size &gt; 5 cm, OR regional nodes positive, or both), Group III (gross residual&#xD;
             disease post-biopsy or attempted resection) embryonal RMS or ectomesenchymoma with&#xD;
             embryonal features&#xD;
&#xD;
          -  Age: ≤ 50 years (inclusive) at the time of diagnosis.&#xD;
&#xD;
          -  Biopsy or definitive surgery within 42 days of start of treatment.&#xD;
&#xD;
        Organ function:&#xD;
&#xD;
          -  Normal renal function: Normal serum creatinine for age or creatinine clearance or&#xD;
             nuclear GFR of ≥ 80 ml/min/1.73m2 (in the absence of obstructive hydronephrosis, e.g.,&#xD;
             from pelvic or bladder/prostate tumor).&#xD;
&#xD;
          -  Normal liver function: Total bilirubin, SGOT/SGPT &lt; 2.5 times the upper limit of&#xD;
             normal (in the absence of hepatic involvement by tumor)&#xD;
&#xD;
          -  Normal cardiac function: echocardiogram shortening fraction ≥ 28% or resting left&#xD;
             ventricular ejection fraction (LVEF) ≥ 50% on Technetium-99m pertechnetate&#xD;
             radionuclide cineangiography (MUGA)&#xD;
&#xD;
          -  Normal hematologic function: absolute neutrophil count (ANC) ≥ 1500/μL, hemoglobin ≥ 9&#xD;
             gm/dL, and platelet count ≥ 100,000/μL (in the absence of bone marrow infiltration by&#xD;
             tumor or the presence of disseminated intravascular coagulation).&#xD;
&#xD;
          -  Measurable disease is not required.&#xD;
&#xD;
          -  Patients must consent to an indwelling central venous catheter.&#xD;
&#xD;
          -  Sexually active patients of childbearing potential must be willing to use an effective&#xD;
             method of contraception.&#xD;
&#xD;
          -  Patient or guardian must be capable of providing informed consent.&#xD;
&#xD;
        SUBJECT EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Prior chemotherapy or radiotherapy (other than limited, emergent radiotherapy for&#xD;
             treatment of threatened airway or cord compromise).&#xD;
&#xD;
          -  Pregnant or breast feeding females because the chemotherapy administered on this trial&#xD;
             could have a detrimental effect on the developing fetus or newborn.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard H. Wexler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>childhood malignant mesenchymoma</keyword>
  <keyword>adult malignant mesenchymoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <keyword>stage I adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

